Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment
-
Published:2024-01-05
Issue:1
Volume:10
Page:
-
ISSN:2374-4677
-
Container-title:npj Breast Cancer
-
language:en
-
Short-container-title:npj Breast Cancer
Author:
Zaikova ElenaORCID, Cheng Brian Y. C., Cerda Viviana, Kong EstherORCID, Lai Daniel, Lum AmyORCID, Bates Cherie, den Brok Wendie, Kono Takako, Bourque Sylvie, Chan Angela, Feng Xioalan, Fenton David, Gurjal Anagha, Levasseur Nathalie, Lohrisch Caroline, Roberts Sarah, Shenkier Tamara, Simmons Christine, Taylor SaraORCID, Villa Diego, Miller Ruth, Aguirre-Hernandez Rosalia, Aparicio Samuel, Gelmon KarenORCID
Abstract
AbstractCirculating tumour DNA (ctDNA) detection via liquid biopsy is an emerging alternative to tissue biopsy, but its potential in treatment response monitoring and prognosis in triple negative breast cancer (TNBC) is not yet well understood. Here we determined the prevalence of actionable mutations detectable in ctDNA using a clinically validated cancer gene panel assay in patients with TNBC, without recurrence at the time of study entry. Sequencing of plasma DNA and validation of variants from 130 TNBC patients collected within 7 months of primary treatment completion revealed that 7.7% had detectable residual disease with a hotspot panel. Among neoadjuvant treated patients, we observed a trend where patients with incomplete pathologic response and positive ctDNA within 7 months of treatment completion were at much higher risk of reduced progression free survival. We propose that a high risk subset of early TNBC patients treated in neoadjuvant therapy protocols may be identifiable by combining tissue response and sensitive ctDNA detection.
Funder
Gouvernement du Canada | Canadian Institutes of Health Research Carolyn Baker Triple Negative Breast Cancer Fund, 0BRRG004 BC Cancer Foundation Susan G. Komen
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology
Reference42 articles.
1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021). 2. Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429–4434 (2007). 3. Zagami, P. & Carey, L. A. Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer 8, 95 (2022). 4. Sant, M., Bernat-Peguera, A., Felip, E. & Margelí, M. Role of ctDNA in breast cancer. Cancers 14, 310 (2022). 5. Cohen, S. A., Liu, M. C. & Aleshin, A. Practical recommendations for using ctDNA in clinical decision making. Nature 619, 259–268 (2023).
|
|